BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed HTOO catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:7f95ece9fdb52f298764@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:HTOO P2 readout (est.): AlphaBreak
DESCRIPTION:FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metas
 tatic Castration-Resistant Prostate Cancer (mCRPC)\nNCT06402331 | PHASE2 |
  ACTIVE_NOT_RECRUITING | sponsor: Fusion Pharmaceuticals Inc.\nPrimary com
 pletion date (ESTIMATED)\; top-line results usually follow later.\nTicker 
 HTOO (confidence 0.6)\nSource: https://clinicaltrials.gov/study/NCT0640233
 1\nScheduling/reference data from public records\; dates can move. Not inv
 estment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06402331
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
